Merck & Co., Inc. 4

Merck Animal Health EVP Richard R. DeLuca sold 6,050 shares of Merck common stock on August 6, 2026 for roughly $0.8 million in total proceeds.

On August 6, 2026, Richard R. DeLuca, EVP & President of Merck Animal Health at Merck & Co., Inc., executed three open-market sales of Merck common stock totaling 6,050 shares at weighted average prices between approximately $130.23 and $131.02 per share, for aggregate proceeds of roughly $790,000. The sales were reported as directly held shares (coded "D") and were carried out in multiple trades within narrow intraday price ranges, as noted by the weighted-average price footnotes. Following these transactions, DeLuca continued to hold a substantial direct equity position in Merck, with the filing indicating post‑transaction direct ownership of 155,487 shares, worth an estimated $20.2 million based on the prevailing stock price, suggesting these were portfolio‑management sales rather than a full exit.

Filing Facts

CIK

310158

Ticker

MRK

Form

4

Source Type

fda

Accession

0000310158-26-000217

Alert Tier

6